What is Lucigen?
Headquartered in Middleton, Wisconsin, Lucigen operates as a specialized provider of advanced molecular biology products and services. The company distinguishes itself by engineering proprietary solutions for complex challenges in DNA cloning, protein expression, and next-generation sequencing. By streamlining the workflows associated with genomic research, Lucigen provides essential tools—including high-efficiency competent cells and specialized enzymes—that empower researchers to accelerate experimental timelines. Its market position is defined by a commitment to technical precision and the simplification of intricate laboratory processes, making it a vital partner for academic and commercial life science institutions worldwide.
How much funding has Lucigen raised?
Lucigen has raised a total of $3.9M across 2 funding rounds:
Private Equity
$1.7M
Angel/Seed
$2.2M
Private Equity (2012): $1.7M, investors not publicly disclosed
Angel/Seed (2014): $2.2M, investors not publicly disclosed
Key Investors in Lucigen
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Lucigen?
With the recent infusion of capital, Lucigen is well-positioned to transition into a more aggressive phase of enterprise-level growth. The strategic allocation of these funds will likely prioritize the expansion of its R&D pipeline, specifically targeting the development of next-generation sequencing reagents and high-throughput cloning technologies. As the demand for rapid genomic analysis continues to surge, Lucigen's focus on simplifying complex molecular workflows provides a significant competitive advantage. Future initiatives will likely involve scaling manufacturing capabilities to meet global demand while exploring strategic partnerships to integrate its proprietary technologies into broader diagnostic and therapeutic platforms. This phase of development marks a pivotal shift from niche product innovation to becoming a foundational pillar in the modern genomic research ecosystem.
See full Lucigen company page
